• 作者：Yinan Zheng^a ; ^b ; ¹ ; Brian T. Joyce^a ; ^c ; ¹ ; Elena Colicino^d ; Lei Liu^a ; ^e ; Wei Zhang^a ; ^e ; Qi Dai^f ; Martha J. Shrubsole^f ; Warren A. Kibbe^g ; ^h ; Tao Gao^a ; Zhou Zhang^a ; ⁱ ; Nadereh Jafari^j ; Pantel Vokonas^k ; Joel Schwartz^d ; ^l ; Andrea A. Baccarelli^d ; Lifang Hou^a ; ^e ; ^{l-hou@northwestern.edu" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Epigenetic age ; Cancer risk ; DNA methylation
• 刊名：EBioMedicine
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：5
• 期：Complete
• 页码：68-73
• 全文大小：451 K

•

We prospectively examined blood Δ_age and its ability to predict cancer risks.

•

Epigenetic age older than chronological age elevated cancer risk.

•

Δ_age predicted cancer incidence and mortality in a dose-responsive manner.

•

The Δ_age–cancer relationship was a nonlinear ‘J-shape’ for subjects measured before 2003.

Blood-based epigenetic age is a potential biomarker for cancer early detection.

This study studies a way to calculate your body's age, not based on how old you are, but by measuring a number of markers in your blood — called epigenetic age. This paper also looks at how good epigenetic age over time is at predicting whether you'll get cancer, and whether you'll die from it. The authors found that epigenetic age could be good at predicting both of these things, which means that someday it could be developed into a blood test for diagnosing cancer, and for helping patients figure out how long they'll live.